Aptabio Therapeutics Inc.
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
293780 | KO
Overview
Corporate Details
- ISIN(s):
- KR7293780003
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 흥덕1로 13 타워동 에이504호(영덕동, 흥덕아이티밸리), 용인시
- Website:
- https://aptabio.com/
- Sector:
- Manufacturing
Description
Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-08-25 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2021-08-23 00:00 |
권리락(무상증자)
|
Korean | 3.5 KB | ||
| 2021-08-19 00:00 |
기타경영사항(특허권취득)(자율공시)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
|
Korean | 5.5 KB | ||
| 2021-08-13 00:00 |
반기보고서 (2021.06)
|
Korean | 721.4 KB | ||
| 2021-08-09 00:00 |
주요사항보고서(무상증자결정)
|
Korean | 10.2 KB | ||
| 2021-08-09 00:00 |
주권매매거래정지(무상증자)
|
Korean | 4.6 KB | ||
| 2021-08-09 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.5 KB | ||
| 2021-08-04 00:00 |
기타경영사항(특허권취득)(자율공시)(간질환 치료제(Therapeutic Agent For Liver Disorder))
|
Korean | 5.3 KB | ||
| 2021-07-07 00:00 |
기타경영사항(특허권취득)(자율공시)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
|
Korean | 5.5 KB | ||
| 2021-06-24 00:00 |
기타경영사항(특허권취득)(자율공시)(혈액암 치료제)
|
Korean | 5.4 KB | ||
| 2021-06-14 00:00 |
기타경영사항(특허권취득)(자율공시)(안질환 예방 또는 치료용 점안 조성물)
|
Korean | 5.8 KB | ||
| 2021-05-14 00:00 |
분기보고서 (2021.03)
|
Korean | 727.0 KB | ||
| 2021-04-06 00:00 |
기타경영사항(특허권취득)(자율공시)(혈액암 치료제)
|
Korean | 5.3 KB | ||
| 2021-03-30 00:00 |
정기주주총회결과
|
Korean | 30.9 KB | ||
| 2021-03-30 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.3 KB |
Automate Your Workflow. Get a real-time feed of all Aptabio Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aptabio Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aptabio Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
